ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 21

Pseudostarvation Using the AMPK Activator Metformin Downregulates Inflammation in Rheumatoid Arthritis Synovial Tissue

Lorna Gallagher1, Ursula Fearon2, Douglas J. Veale3, David Kane4, Luke A. O'Neill5 and Ronan Mullan4, 1Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin, Ireland, 2St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland, 3St Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland, 4Department of Rheumatology, Tallaght Hospital, TCD, Dublin 24, Ireland, 5Inflammation Research, School of Biochemistry and Immunology, Trinity College Dublin, Dublin, Ireland

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Fibroblasts, metabolism and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: AMP-activated protein kinase (AMPK) is a highly conserved, regulator of cellular energy status. In inflammation, AMPK inactivation is associated with increased glucose consumption through aerobic glycolysis, and up-regulation of pro-inflammatory effector responses. Pseudostarvation of cells via AMPK activation by hypoglycaemic therapy, i.e. Metformin, reverses these effects.  AMPK activity has a cascade effect on other mediators of cell metabolism, including Acetyl-CoA Carboxylase (ACC). Once activated, phosphorylated AMPK (P-AMPK) in turn phosphorylates ACC (P-ACC). AMPK/ACC interactions play a central role in the regulation of cellular lipid homeostasis. Here we demonstrate AMPK activation in RA synovial tissues (RAST), and inhibition of pro-inflammatory responses in stimulated primary RA synovial fibroblast cells (RASFCs) following pharmacological AMPK activation by Metformin in vitro.

Methods: P-AMPK, AMPK, P-ACC and ACC expression in RAST and RASFCs were analyzed by immunoblotting, normalized against β-actin.  RASFCs were stimulated with LPS or TNFα (10 ng/ml) in the presence of Metformin (0 – 62.5 µM) and assessed for wound healing and invasion capabilities. Culture supernatants were evaluated for IL-6 and IL-8 production by ELISA. RAST, obtained from RA patients during arthroscopy, were stained by immunohistochemistry for Phosphorylated ACC (P-ACC) and ACC, and by Immunofluorescence for P-AMPK and AMPK.

Results: Western blot analysis showed that P-AMPK was present in RAST, and cultured RASFCs. P-AMPK expression was upregulated in the presence of Metformin (10 µM & 50 µM).  Stimulating cells, with either LPS or TNFα (10 ng/ml), in the presence of Metformin (10 µM & 50 µM) increased P-AMPK, expression was greater than what was observed following LPS or TNFα stimulation alone. Additionally, LPS stimulated cells in the presence of Metformin (10 µM & 50 µM) showed P-ACC expression, which was not observed in LPS stimulated cells alone. In vitro immunofluorescence staining of RASFCs showed P-AMPK upregulation both in the presence of Metformin (50 µM) compared to basal and TNFα (10 ng/ml) stimulated RASFCs. Positive immunohistochemistry staining of RAST for P-ACC, indicated that AMPK is activated and in its phosphorylated state, with maximal expression localized around blood vessels. Stimulation of RASFCs with LPS or TNFα (10 ng/ml) in the presence of Metformin (15 – 62.5 µM) decreased IL-6 and IL-8 production in a dose dependent manner. RASFCs stimulated with either LPS or TNFα (10 ng/ml) in the presence of Metformin (15 – 62.5 µM) showed a dose dependent decrease in the ability of the cells to heal an induced wound or invade through matrigel.

Conclusion: Our findings indicate that RAST and RASFCs are capable of responding to pharmacological alterations in cellular metabolic pathways. Metformin both activates AMPK and downregulates pro-inflammatory effects in RA. AMPK activation occurs in concert with P-ACC around blood vessels but not in the lining layer where matrix metalloproteinase mediated joint destruction occurs, in keeping with an anti-inflammatory role for activated AMPK.  AMPK activation therapy pathways may therefore be a suitable future strategy in the treatment of Rheumatoid Arthritis.


Disclosure: L. Gallagher, None; U. Fearon, None; D. J. Veale, None; D. Kane, None; L. A. O'Neill, None; R. Mullan, None.

To cite this abstract in AMA style:

Gallagher L, Fearon U, Veale DJ, Kane D, O'Neill LA, Mullan R. Pseudostarvation Using the AMPK Activator Metformin Downregulates Inflammation in Rheumatoid Arthritis Synovial Tissue [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/pseudostarvation-using-the-ampk-activator-metformin-downregulates-inflammation-in-rheumatoid-arthritis-synovial-tissue/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pseudostarvation-using-the-ampk-activator-metformin-downregulates-inflammation-in-rheumatoid-arthritis-synovial-tissue/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology